Pharmena S.A. (PHR) - Total Assets
Based on the latest financial reports, Pharmena S.A. (PHR) holds total assets worth zł11.39 Million PLN (≈ $3.13 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Pharmena S.A. - Total Assets Trend (2008–2024)
This chart illustrates how Pharmena S.A.'s total assets have evolved over time, based on quarterly financial data. Also see PHR market cap for the company's overall valuation and market capitalisation.
Pharmena S.A. - Asset Composition Analysis
Current Asset Composition (December 2024)
Pharmena S.A.'s total assets of zł11.39 Million consist of 87.8% current assets and 12.2% non-current assets. Review debt load of Pharmena S.A. to assess the company's total debt and financial obligations.
| Asset Category | Amount (PLN) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 12.9% |
| Accounts Receivable | zł76.00K | 0.6% |
| Inventory | zł689.00K | 5.1% |
| Property, Plant & Equipment | zł0.00 | 0.0% |
| Intangible Assets | zł1.13 Million | 8.4% |
| Goodwill | zł0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Pharmena S.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See PHR live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pharmena S.A.'s current assets represent 87.8% of total assets in 2024, an increase from 84.1% in 2008.
- Cash Position: Cash and equivalents constituted 12.9% of total assets in 2024, down from 70.9% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, a decrease from 9.0% in 2008.
- Asset Diversification: The largest asset category is intangible assets at 8.4% of total assets.
Pharmena S.A. Competitors by Total Assets
Key competitors of Pharmena S.A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Pharmena S.A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.52 | 16.64 | 0.74 |
| Quick Ratio | 12.58 | 15.77 | 0.38 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | zł9.00 Million | zł11.27 Million | zł-2.87 Million |
Pharmena S.A. - Advanced Valuation Insights
This section examines the relationship between Pharmena S.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.70 |
| Latest Market Cap to Assets Ratio | 0.70 |
| Asset Growth Rate (YoY) | -43.9% |
| Total Assets | zł13.53 Million |
| Market Capitalization | $9.53 Million USD |
Valuation Analysis
Below Book Valuation: The market values Pharmena S.A.'s assets below their book value (0.70x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Pharmena S.A.'s assets decreased by 43.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Pharmena S.A. (2008–2024)
The table below shows the annual total assets of Pharmena S.A. from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | zł13.53 Million ≈ $3.72 Million |
-43.95% |
| 2023-12-31 | zł24.13 Million ≈ $6.64 Million |
+91.84% |
| 2022-12-31 | zł12.58 Million ≈ $3.46 Million |
+12.81% |
| 2021-12-31 | zł11.15 Million ≈ $3.07 Million |
+1.84% |
| 2020-12-31 | zł10.95 Million ≈ $3.01 Million |
-6.73% |
| 2019-12-31 | zł11.74 Million ≈ $3.23 Million |
+72.57% |
| 2018-12-31 | zł6.80 Million ≈ $1.87 Million |
-38.73% |
| 2017-12-31 | zł11.10 Million ≈ $3.06 Million |
-22.26% |
| 2016-12-31 | zł14.28 Million ≈ $3.93 Million |
-5.77% |
| 2015-12-31 | zł15.16 Million ≈ $4.17 Million |
-10.12% |
| 2014-12-31 | zł16.86 Million ≈ $4.64 Million |
-17.97% |
| 2013-12-31 | zł20.56 Million ≈ $5.66 Million |
+77.38% |
| 2012-12-31 | zł11.59 Million ≈ $3.19 Million |
-35.80% |
| 2011-12-31 | zł18.05 Million ≈ $4.97 Million |
+7.32% |
| 2010-12-31 | zł16.82 Million ≈ $4.63 Million |
-1.60% |
| 2009-12-31 | zł17.09 Million ≈ $4.70 Million |
+3.48% |
| 2008-12-31 | zł16.52 Million ≈ $4.55 Million |
-- |
About Pharmena S.A.
Pharmena S.A., a biotechnology company, manufactures and sells active ingredients in various areas of medicines in Poland and internationally. The company offers dermatological cosmetics, including face, hair, and body care products, as well as dietary supplement. It offers its products under the Menavitin, Dermena, Allerco, and Thermi names. Pharmena S.A. was founded in 2002 and is based in Lódz… Read more